Portfolio PR – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF

2025.07.172025.07.17 / Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA ...

VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery

2025.07.092025.07.09 / Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation, enabling urgent surgery in patients taking a ...

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

2025.05.072025.05.07 / -Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009’s unique mechanism of action depletes pathogenic T and B ce ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present Phase 2a data on Nck modulatorAX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting

2025.04.252025.04.30 / Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced ...

AnaCardio receives patent grant in Europe for AC01

2025.03.132025.04.30 / Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present on first-in-class Nck modulator at the 2025 AAD Annual Meeting

2025.03.032025.04.30 / Poster presentation on evaluation of Nck modulator in atopic dermatitis models Cambridge, MA, March 3, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on tran ...

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

2025.02.272025.04.30 / February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first pa ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

2025.01.222025.04.30 / Novel breakthrough: first molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related ...

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

2024.12.172025.04.30 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

2024.11.192025.04.30 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...

VarmX announces appointment of John Glasspool as CEO

2024.11.122025.04.30 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...

ARTHEx biotech

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

2024.10.212025.04.30 / VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expressi ...